Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20788520 | 0.83 | FYN (0.46) | FYNCHEK2EGFRPARP1FGFR1 | |
| SCHEMBL20788509 | 0.78 | IKBKB (0.55) | FYNIKBKBCHEK1BCAT2BRD4 | |
| SCHEMBL4966792 | 0.71 | BCAT2 (0.59) | BCAT2NPC1RAB9A | |
| SCHEMBL20788513 | 0.71 | HDAC2 (0.76) | HDAC2 | |
| SCHEMBL18613475 | 0.69 | FYN (1.00) | FYNCHEK2CHEK1 | |
| SCHEMBL4260834 | 0.69 | MAPT (0.56) | FYNNPC1RAB9A | |
| SCHEMBL4963646 | 0.69 | BCAT2 (0.65) | PARP1BCAT2FGFR1SRCFGFR2 | |
| SCHEMBL30521908 | 0.68 | FYN (1.00) | FYNCHEK2CHEK1 | |
| SCHEMBL18613268 | 0.68 | FYN (1.00) | FYNCHEK2CHEK1 | |
| SCHEMBL5306467 | 0.68 | IKBKB (0.65) | IKBKBCHEK2CHEK1PARP1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | INSTITUTE OF NUCLEAR ENERGY RESEARCH, NUCLEAR ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2019-03-14 | — | — | US | claimed |
| US-10507250-B2 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2019-12-17 | — | — | US | disclosed |
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | INSTITUTE OF NUCLEAR ENERGY RESEARCH, NUCLEAR ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10507250-B2 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | H1-3, H1-2, HDAC2 | FYN 3784/4885IKBKB 1640/4885CHEK2 1824/4885 |
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | H1-3, H1-2, HDAC2 | FYN 3784/4885IKBKB 1640/4885CHEK2 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.